| Literature DB >> 35467375 |
Nina S Smirnova1, Alexey V Kostarnoy1, Alexey V Kondratev1, Petya G Gancheva2, Daniil A Grumov1, Alexander L Gintsburg3.
Abstract
Tick-borne spotted fevers caused by Rickettsia occur worldwide. The symptoms of this bacterial infection are similar to those of viral infection, and thus, diagnostic accuracy has special clinical importance. One of the commonly used methods for the diagnosis of tick-borne spotted fever is enzyme-linked immunosorbent assay (ELISA), which is based on estimation of the presence of specific IgM antibodies in blood. However, IgA analysis has not been used for the diagnosis of rickettsial diseases thus far. We investigated the diagnostic value of IgA antibody determination using patient sera collected in the Astrakhan region of Russia, where an isolated site of Astrakhan rickettsial fever (ARF) caused by Rickettsia conorii subsp. caspia is located. Our investigation was performed on serum samples collected from 185 patients diagnosed with Astrakhan rickettsial fever from May to October 2019. Western blot analysis revealed that specific IgA antibodies, as well as IgM antibodies, from patient sera bind to high-molecular-weight pathogen proteins with similar masses. The obtained data show that the determination of IgM alone allows for serological confirmation of diagnosis in only 46.5% of cases but that the determination of both IgM and IgA increases this rate to 66.5%. Taken together, the findings show an important diagnostic value of IgA evaluation for tick-borne spotted fever rickettsiosis. IMPORTANCE Tick-borne spotted fevers caused by Rickettsia occur worldwide. The symptoms of this bacterial infection are similar to the symptoms of viral infection, and thus, diagnostic accuracy has special clinical importance. The most serious spotted fever group rickettsiosis is Rocky Mountain fever in the United States, which is caused by Rickettsia rickettsii, and disease complications can lead to hemiparesis, blindness, or amputation. Rickettsia conorii subsp. caspia causes a rickettsial spotted fever named Astrakhan rickettsial fever (ARF). One of the commonly used methods for the diagnosis of tick-borne spotted fevers is ELISA, which is based on estimation of the presence of specific IgM antibodies in blood, though IgA has not been used for the diagnosis of rickettsial diseases thus far. In this study, we showed that both IgA and IgM should be analyzed in the blood serum samples of patients to significantly enhance the accuracy of diagnostics of tick-borne spotted fever rickettsiosis.Entities:
Keywords: ELISA; IgA; rickettsiosis; serology; tick-borne spotted fever
Mesh:
Substances:
Year: 2022 PMID: 35467375 PMCID: PMC9241626 DOI: 10.1128/spectrum.01687-21
Source DB: PubMed Journal: Microbiol Spectr ISSN: 2165-0497
FIG 1Map showing the location of the Astrakhan region, where ARF is endemic. Map drawn by author A. V. Kondratev.
FIG 2Western blotting of the combined serum specimens of patients with ARF. Rickettsia conorii proteins were separated via SDS-PAGE and stained using EZblue reagent (left panel) or transferred onto nitrocellulose membranes and probed with the combined patient serum samples, followed by incubation with IgA- or IgM-specific secondary antibodies (right panels).
Patient demographic data and results of IgA and IgM evaluation in sera
| Demographic or disease characteristic | Total, | IgM positive | IgA positive | ||
|---|---|---|---|---|---|
|
| % |
| % | ||
| Patients with ARF ( | |||||
| Sex | |||||
| Female | 83 | 45 | 54.2 | 32 | 38.6 |
| Male | 97 | 39 | 40.2 | 40 | 41.2 |
| Unknown | 5 | 2 | 40.0 | 4 | 80.0 |
| Age, yr | |||||
| <3 | 3 | 3 | 100.0 | 1 | 33.3 |
| 3–18 | 38 | 27 | 71.1 | 15 | 39.5 |
| 18–44 | 33 | 18 | 54.5 | 11 | 33.3 |
| 45–59 | 44 | 15 | 34.1 | 14 | 31.8 |
| 60–74 | 58 | 20 | 34.5 | 30 | 51.7 |
| 75–89 | 8 | 3 | 37.5 | 4 | 50.0 |
| Unknown | 1 | 0 | 1 | 100.0 | |
| Fever duration, days | |||||
| <3 | 50 | 23 | 46.0 | 14 | 28.0 |
| 4–6 | 72 | 34 | 47.2 | 29 | 40.3 |
| 7–16 | 59 | 28 | 47.5 | 30 | 50.8 |
| Unknown | 4 | 1 | 25.0 | 3 | 75.0 |
| Q-fever-seropositive patients ( | |||||
| Sex | |||||
| Female | 4 | 0 | 0 | ||
| Male | 9 | 0 | 0 | ||
| Age, yr | |||||
| 3–18 | 2 | 0 | 0 | ||
| 18–44 | 6 | 0 | 0 | ||
| 45–59 | 2 | 0 | 0 | ||
| 60–74 | 2 | 0 | 0 | ||
| 75–89 | 1 | 0 | 0 | ||
| Fever duration, days | |||||
| 4–6 | 4 | 0 | 0 | ||
| 7–16 | 7 | 0 | 0 | ||
| Unknown | 2 | 0 | 0 | ||
| Healthy persons ( | |||||
| Sex | |||||
| Female | 6 | 0 | 0 | ||
| Male | 12 | 0 | 0 | ||
| Age, yr | |||||
| <3 | 1 | 0 | 0 | ||
| 3–18 | 1 | 0 | 0 | ||
| 18–44 | 8 | 0 | 0 | ||
| 45–59 | 4 | 0 | 0 | ||
| 60–74 | 2 | 0 | 0 | ||
| 75–89 | 2 | 0 | 0 | ||
FIG 3Analysis of blood serum samples via ELISA. (A) The results of specific IgA and IgM presence in the sera of patients. The number of positive samples and percentage of total are presented. (B) Venn diagram showing the percentage of total IgA-positive, IgM-positive, and double IgA/IgM-positive sera.
FIG 4The titer and the number of positive samples according to the day after disease onset. Each positive serum sample is depicted as a dot.
Evaluation of IgA and IgM titers in patients’ sera
| Day after disease onset |
| No. IgA pos, IgM neg (titer[s]) | No. IgM pos, IgA neg (titer[s]) | No. IgA pos, IgM pos (titer[s] of IgA and IgM) | No. IgA neg, IgM neg |
|---|---|---|---|---|---|
| 0 | 1 | 1 | |||
| 1 | 6 | 3 (1/640, 1/640, 1/640) | 2 (1/640, 1/640) | 1 (1/640 and 1/640) | |
| 2 | 17 | 1 (1/80) | 4 (1/640, 1/640, 1/160, 1/80) | 4 (1/640 and 1/640, 1/40 and 1/640, 1/80 and 1/640, 1/20 and 1/640) | 8 |
| 3 | 26 | 4 (1/640, 1/640, 1/40, 1/80) | 11 (1/640, 1/640, 1/640, 1/640, 1/640, 1/640, 1/640, 1/640, 1/320, 1/160, 1/80) | 1 (1/640 and 1/80) | 10 |
| 4 | 19 | 6 (1/640, 1/640, 1/640, 1/320, 1/320, 1/320) | 6 (1/640, 1/640, 1/160, 1/160, 1/160, 1/320) | 3 (1/640 and 1/640, 1/640 and 1/160, 1/640 and 1/640) | 4 |
| 5 | 28 | 5 (1/20, 1/20, 1/20, 1/320, 1/320) | 9 (1/640, 1/640, 1/640, 1/640, 1/640, 1/640, 1/640, 1/160, 1/80) | 5 (1/80 and 1/320, 1/640 and 1/640, 1/160 and 1/640, 1/80 and 1/160, 1/640 and 1/640) | 9 |
| 6 | 25 | 4 (1/640, 1/640, 1/40, 1/80) | 5 (1/640, 1/640, 1/640, 1/640, 1/640) | 6 (1/640 and 1/320, 1/640 and 1/640, 1/640 and 1/80, 1/320 and 1/640, 1/40 and 1/640, 1/80 and 1/640) | 10 |
| 7 | 17 | 1 (1/640) | 1 (1/80) | 5 (1/640 and 1/640, 1/640 and 1/640, 1/640 and 1/640, 1/640 and 1/640, 1/320 and 1/640) | 10 |
| 8 | 16 | 6 (1/640, 1/640, 1/320, 1/160, 1/80, 1/20) | 4 (1/640, 1/160, 1/80, 1/80) | 2 (1/640 and 1/640, 1/80 and 1/640) | 4 |
| 9 | 7 | 1 (1/640) | 1 (1/640) | 3 (1/640 and 1/40, 1/640 and 1/40, 1/640 and 1/40) | 2 |
| 10 | 9 | 3 (1/40, 1/40, 1/640) | 1 (1/640) | 2 (1/640 and 1/640, 1/640 and 1/640) | 3 |
| 11 | 3 | 1 (1/640) | 2 (1/80, 1/640) | ||
| 12 | 3 | 3 (1/640 and 1/640, 1/640 and 1/640, 1/640 and 1/640) | |||
| 13 | |||||
| 14 | 1 | 1 (1/640) | |||
| 15 | |||||
| 16 | 3 | 3 (1/640 and 1/640, 1/640 and 1/640, 1/640 and 1/640) |
pos, positive; neg, negative.
Quantification of LPS and protein content and evaluation of antigenic activity in chromatography-purified LPS and protein fraction and in isolated LPS
| Antigen | Quantity per mL (measured) | Quantity per well antigen dilution (calculated) | Titer | |||
|---|---|---|---|---|---|---|
| LPS, EU | Protein, μg | LPS, EU | Protein, μg | IgA | IgM | |
| Chromatographically purified LPS | 7.3 × 104 | 340 ± 14 | 2.1 × 102 | 1 | 8 sera, 1/640 | 8 sera, 1/640 |
| Protein fraction | <5 | 138 ± 5 | <0.04 | 1 | 8 sera, 1/640 | 8 sera, 1/640 |
| LPS | 2.3 × 105 | <15 | 2.1 × 102 | <0.014 | 4 sera, 1/640; 4 sera, negative | 8 sera, 1/640 |
EU, endotoxin units.